However, new and improved tools are required for both diseases; for AAT as a tool to begin to reduce the current significant infection burden, and for HAT to facilitate the delivery of the WHO aim of HAT elimination by 2030 [4, 5]. This evidence concerns the gene SERPINA1 and infection.